Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Ready to fly

Sangamo Therapeutics (SGMO) shares were up over 15% amid a license deal granting Astellas Pharma worldwide rights to its neurotropic adeno-associated virus capsid, STAC-BBB, for neurological disease targets, the companies said. The consideration for the deal includes a $20 million upfront license payment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
Translate
Report
1786 Views
Comment
Sign in to post a comment